[August 02, 2011]

Cannabis Science To Launch A Worldwide Online Cannabis Patient Tracking System For Patients, Doctors, and Company Interactions Over The Internet

Cannabis Science Inc. (NASD OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased announce its plans to launch an online cannabis patient tracking system, which will be made available worldwide for private and secure usage and results tracking. This new initiative is based on the large amount of new inquiries from patients, relatives, and friends from all over the world; all inquiring about treatments for various critical ailments the Company has been focused on for Cannabis Science's proprietary medical cannabis delivery methods and formulations.

The Company is in the process of creating a new section on its website to allow all Company approved users can track their usage and provide valuable patient input, and medical documentation regarding their experiences with medical marijuana and cannabis extracts. This data will go hand in hand with our licensed product development partners and their patients who wish to use it all adding to the cumulative international research and present critical patient dat so that other patients may make informed decisions regarding their health care treatment options while furthering our studies and product development.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "We feel it is essential that CBIS work with patients around the world to foster policy changes that will increase the demand and availability of our products, in line with our expanding business opportunities that are developing through new partnerships and license agreements to maximize market potential for the Company and shareholders."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

[ Back To TMCnet.com's Homepage ]